Company ProfilePremium

Cytogen, Inc.

Company Profile Analysis

Ticker: 217330.KQ주식회사 싸이토젠

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cytogen, Inc. - Company showcase

Year Founded & Workforce

2010

43 Employees

Cytogen, Inc. logo

Cytogen, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cytogen, Inc. Overview

Cytogen is a small-cap Korean precision-medicine company that began as a pure-play developer of circulating tumour cell (CTC) liquid biopsy technology. Its core asset is a proprietary high-density microporous (HDM) chip and the Smart Biopsy™ platform. The platform isolates CTCs from blood by size, without labels, and keeps the cells alive, so they can be cultured, single-cell sequenced and turned into organoids. Commercial traction from CTC services alone was minimal for a decade: revenue was below KRW 1.2 B in every year through 2022. Since a December 2023 change of control to the CanDx Holdings consortium, Cytogen has diversified through acquisitions. It bought a US CLIA/CAP toxicology lab (ExperTox) in January 2023 and Korea's self-described number-one NIPT/PGT provider (Genomecare) in August 2024. It has also added medical-device distribution. Revenue reached KRW 26.1 B in FY2025, but the company remains loss-making. Management now presents Cytogen as a "life-cycle precision medicine" platform spanning fertility genomics, cancer diagnostics and an early-stage anti-metastasis drug programme.


The company's own description

In its periodic reports, Cytogen describes itself as a CTC-based liquid biopsy platform company. It uses proprietary "Live CTC" isolation technology to provide biomarker analysis and companion-diagnostic assay development for pharmaceutical companies developing oncology drugs (Q1 2026 quarterly report, as summarized by ValueLine). The same filing summary lists the main activities:

  • CTC analysis services for pharmaceutical companies on the Smart Biopsy™ platform

  • Data provision and kit supply for research institutions

  • Precision-medicine diagnostic services

  • Global expansion through the acquisition of a Texas CLIA lab and the establishment of a Japanese subsidiary

  • Diversification into medical-device distribution and health-functional-food sales

  • Acquisition of the prenatal/postnatal diagnostics company Genomecare in 2024, to secure stable cash flow

The Q1 2026 quarterly report states that the August 2024 Genomecare acquisition, which covers PGT and NIPT across the journey from IVF to delivery, "improved cash flow and strengthened consolidated financial results" (KIND, Q1 2026 quarterly report extract).

In July 2026, explaining the Genomecare merger, the company said it now has two core businesses:

  • CTC-based precision medicine, framed as the future growth engine

  • Prenatal and pre-implantation genetic testing, which already generates stable profits

The stated ambition is to become a "full life-cycle precision medicine company", from pre-implantation genetic testing through prenatal diagnosis to cancer precision diagnosis and treatment support (Seoul Economic Daily / SEN TV, 29 July 2026).

Business model and revenue model

Revenue streamModel typeDescriptionApproximate share
Genome technology development and analysis services (Genomecare: NIPT, PGT)Fee-for-service diagnostics, mostly B2B2C via fertility and obstetric clinicsPer-test fees for non-invasive prenatal testing and pre-implantation genetic testing~47% of revenue (Q2 2026 basis)
Liquid biopsy application businessMixed: services (B2B pharma contract analysis; Japanese premium out-of-pocket tests), product sales (Smart Biopsy™ instruments, chips, kits), equipment contracts (e.g. digital lab-on-chip automation system), plus distribution of medical devices and health-functional foodCTC enumeration and characterization, drug-efficacy evaluation, CDx assay development; Japan CTC services; distribution~48% (Q2 2026 basis)
Toxicology and molecular diagnostics (ExperTox, Houston, Texas)Fee-for-service laboratory testingCLIA/CAP-accredited toxicology testing for 100+ US hospitals and labs~6% (Q2 2026 basis)
Licensing / royaltiesNot a material disclosed streamOut-licensing of anti-metastasis candidates is contemplated, not yet realized0%

Cytogen's revenue model has four layers:

The segment mix is from the Butler.works summary of DART filings ("Liquid Biopsy application 48% · Genome technology development and analysis service 47% · Toxicology and molecular diagnostics 6%", 2026 Q2 revenue basis). The shares sum to 101% because of rounding at source.

Two points stand out. First, a large portion of the "Liquid Biopsy application" segment appears to consist of low-margin distribution revenue rather than CTC technology revenue. Medical-device distribution (for example, medical gloves) generated KRW 1.5 B in Q3 2024 alone (thebell, March 2025). Second, the precise split between CTC services, equipment and distribution inside that segment is not publicly disclosed in accessible summaries.

Value-chain position

CTC business: Cytogen sits upstream as a platform developer and instrument maker (HDM chip, isolator, stainer, imaging analyser). It sits midstream as a GCLP-certified central lab offering analysis services. In Japan it is beginning to move downstream into patient-facing (B2C) out-of-pocket testing through hospital partners such as Japan's National Cancer Center Hospital.

Genomecare: A downstream clinical laboratory service provider. It receives samples from fertility clinics and obstetricians and returns NGS/AI-based genetic reports.

ExperTox: A downstream US reference laboratory.

Customer types and end-markets

Customer typeExamples (disclosed)End-market
Global and domestic pharma/biotechDaiichi Sankyo (2018 AXL biomarker research); pharma clients in Japan via CMIC marketing agreementOncology drug development (biomarkers, CDx)
Hospitals / academic medical centresSamsung Medical Center, Asan Medical Center, Seoul National University Hospital, Seoul St. Mary's, Severance, Gangnam Severance; Japan NCCHClinical research, precision oncology
Government / research institutesUS NIH (platform supply, 2022); Gangwon Regional Public Procurement Service (2025 automation-system contract)Research infrastructure
Fertility clinics and obstetricians (Genomecare)Described as "top fertility hospitals nationwide" (names not disclosed)Reproductive genomics (NIPT, PGT)
US hospitals and labs (ExperTox)100+ hospitals and labs in Houston, TexasToxicology testing

Independent characterization

On the evidence, Cytogen is not a scaled CTC diagnostics company. It is a holding-like small cap whose consolidated revenue is now driven by an acquired reproductive-genomics lab and by distribution activities. That revenue funds a sub-scale but technically differentiated CTC platform and a newly announced drug-discovery venture.

The NIPT/PGT unit is genuinely profitable: FY2025 standalone operating margin was about 27%. It is the economic anchor. The CTC franchise has struggled for more than a decade to convert scientific credibility into recurring revenue. That credibility includes NIH platform supply, Japanese NCCH collaboration and AACR presentations.

The strategy pursued since 2024 under CanDx-aligned management (portfolio diversification, bio-robotics, PRP automation, anti-metastasis drugs) widens the scope considerably relative to the company's balance sheet. The repeated governance conflicts between the founder and the controlling shareholder are a distinctive feature of the investment case.

Strategy

Stated strategy (themes from company disclosures)

Cytogen's corporate statement (Korean Wikipedia, drawing on company material):

Mission: "pursue optimal solutions for a better future for humanity".

Vision: "global leader in liquid biopsy leading human health".

  • Five management strategies, including:

    • advancement of the CTC business strategy

    • acceleration of new-business development

    • increase in future value

Under CEO Ahn (from February 2026) the themes are:

  1. Simplify decision-making to maximize execution.

  2. Advance CTC technology and achieve "real results in global markets".

  3. Build new growth axes: BioRobot division, precision and regenerative medicine, and infertility solutions via Genomecare. The goal is to evolve from a CTC single-business structure into a "global precision-medicine platform company".

  4. Sustainable profitability: "establish a sustainable revenue model and increase corporate value".

  5. Balance R&D and stable earnings. Ahn stated that a bio company needs both future-facing R&D capability and a stable profit base, and that the Genomecare acquisition and merger were consistent steps toward that goal (July 2026).

Strategic initiatives in the last 24 months (Oct 2024–Oct 2026)

InitiativeDateDescriptionTargets / status
Founder–controller settlement and co-CEO structureJan–Mar 2025Ended the Hyulim Networks-backed dispute; founder ran CTC, Ahn ran new businessesSuperseded by sole-CEO structure (Feb 2026)
2025 "top-line growth" planMar 2025Aggressive promotion in the US and Japan; domestic drug-monitoring analysis services with clinical-stage biotechs; Genomecare expected to deliver KRW 10 B+ annual revenue; medical-device distributionGenomecare delivered KRW 10.96 B (FY2025)
Digital lab-on-chip automation systemNov 2025First government equipment contract (KRW 1.05 B)Delivery by Nov 2026
BioRobot divisionFeb 2026Combines cell-based diagnostics with automationNewly created; no revenue disclosed
Head-office move to GwacheonMar 2026Relocation to Gwacheon Urban Hub, a growing pharma/bio clusterCompleted
Anti-metastasis drug programmeJul 2026CTC-derived omics data used to discover and validate targetsNon-clinical completion in 3–4 years; early-stage out-licensing contemplated
Genomecare absorption mergerJul–Oct 2026Integrates fertility genomics into parent; removes duplicate costs; cash flow redeployed to CTC advancement, anti-metastasis drugs and next-generation reproductive medicineCompleted 1 Oct 2026
Reproductive-medicine synergiesFrom Jul 2026Embryo-biopsy cell QC standardization; cell-based NIPT; PRP automation linked to fertility clinicsR&D / early commercialization
Japan three-pillar push2,026CTC, PRP and prenatal testing in Japan; BioJapan participation (third year)Ongoing
Two national R&D projectsSep 2026Extend the CTC "diagnosis → treatment" value chainSelected
Employee incentive alignmentAug 2026400,000 stock options to 11 staff at KRW 3,280 (exercisable 2028–2033). Total outstanding options 1,016,791 shares.Granted

ESG / cost programmes / medium-term targets

Cost programme: "company-wide efficient SG&A reduction" cited for the Q1 2026 improvement. No quantified target disclosed.

Medium-term financial targets / guidance: not publicly disclosed. A 2023 aspiration of about 50% average annual revenue growth (founder Jeon, Feb 2023) was a stated expectation, not formal guidance.

ESG commitments: none disclosed.

Products & Services

CTC / Liquid Biopsy Platform (Smart Biopsy™)

Product / serviceDescription and key capabilitiesTarget customerLaunch / latest versionPricing
HD Microporous (HDM) ChipSemiconductor-process microfluidic filter chip. Captures CTCs by size, label-free (no EpCAM dependence), driven by gravity to minimize cell damage. Enables "Live CTC" isolation for downstream culture and molecular work.Labs, pharma, hospitalsCore technology since about 2008–2012—
Smart Biopsy™ Cell Isolator (CIS030 referenced)Automated enrichment of CTCs from 5–10 ml of blood or body fluid. Company-reported recovery rate of 79–82%.Clinical labs, research institutes, pharmaModel CIS030 referenced in KoreaRatings 2024 tech report—
Smart Biopsy™ IF Stainer (CST030 referenced)Automated immunofluorescent staining (anti-EpCAM, anti-CD45, anti-CK and other markers)SameReferenced 2024—
Smart Biopsy™ Cell Image AnalyzerMulti-channel fluorescent imaging and analysis. Company states it cut analysis time from about 3 hours to 30 minutes.Same——
Time-lapse IncubatorMonitors cell growth and images cells in culture plates (for CTC culture)Research——
CTC enumeration and characterization services (GCLP lab)Isolation, counting and phenotyping; protein biomarkers such as PD-L1Pharma (clinical trials), hospitalsCommercial since 2012Per sample (not disclosed). In 2017–18 the company said PD-L1 liquid biopsy could cost 1/5–1/10 of tissue biopsy.
Drug-efficacy evaluation / biomarker discovery and validationUses CTCs and CTC culture/animal models to test anticancer drug responsePharma / biotechOngoingContract-based
Companion-diagnostic (CDx) assay developmentDevelops CTC-based assays to select patients for targeted therapiesPharmaOngoingContract-based
CTC single-cell RNA sequencingSingle-cell transcriptomics of isolated CTCs (e.g. Gangnam Severance breast cancer study, 2023; Macrogen collaboration)Hospitals, research2022–2023Contract-based
CTC 3D organoids / drug sensitivity testingOrganoid culture from patient CTCs to select personalized therapyHospitals, patientsIn development / research use—
Japan CTC analysis services (CytoGen Japan)Local CTC testing; targets the non-reimbursed premium out-of-pocket marketJapanese hospitals, patients, pharmaRevenue began late 2025—
Digital lab-on-chip automated production system (chip automation system)Automated line for producing digital lab-on-chip devices; KRW 1.05 B contract with Gangwon Regional Public Procurement Service (Chuncheon)Public-sector / regional bio-clusterContract Nov 2025, delivery by Nov 2026KRW 1.05 B per system (VAT excl.)
Pet cancer diagnostics; AI data analysisListed among offerings by a data vendorVeterinary / data clients——

Sources for the platform: Yahoo Finance and Simply Wall St company descriptions; Biospectator; Dealsite (Jul 2023); KoreaRatings tech report (Aug 2024); Digital Today (Nov 2025); Craft.co.

Reproductive Genomics ("Genomecare by CytoGen")

Product / serviceDescriptionTarget customerNotes
NIPT (non-invasive prenatal testing)cfDNA-based fetal chromosomal aneuploidy screening from maternal blood; AI/NGS-basedObstetric clinics, pregnant womenCompany claims domestic No.1 position in NIPT and PGT (company statement)
PGT (pre-implantation genetic testing): Genobro™ (지노브로)Analyses cells biopsied from IVF embryos to select chromosomally normal embryos, aiming to raise implantation and pregnancy rates and lower miscarriage riskFertility (IVF) clinicsSupplied to "top fertility hospitals nationwide"
Cell-based NIPT (R&D)Isolation and analysis of rare fetal-origin cells (e.g. circulating trophoblasts) in maternal blood, using Cytogen's rare-cell platform; meant to complement cfDNA NIPTFutureMedium/long-term R&D (announced Jul 2026)
Embryo biopsy QC / standardized pre-processingUses Cytogen's rare-cell imaging and handling to standardize PGT trophectoderm-cell QCFertility clinicsPlanned post-merger synergy

Toxicology & Molecular Diagnostics (ExperTox, USA)

ServiceDescriptionCustomers
Toxicology testingCLIA-certified, CAP-accredited lab founded 1996; specializes in toxicology tests100+ hospitals and research labs in Houston; the company cited Abbott and other pharma/hospitals as main partners (2023)
Molecular diagnostics (expansion)Was pursuing additional CAP accreditation in molecular diagnostics at acquisition; intended as the US platform for CTC servicesUS clinical market

At acquisition, ExperTox revenue was about US$3 M (2022), with net margin above 20% excluding COVID testing (company statement, Jan 2023).

New / Diversified Businesses

BusinessDescriptionStatus
Medical-device distributionDistribution of items such as medical glovesKRW 1.5 B revenue in Q3 2024 (thebell). Ongoing.
Health-functional food salesSale of health-functional foodsOngoing (size not disclosed)
PRP (platelet-rich plasma) automatic separation/extraction systemAutomated PRP processing to be linked with Genomecare's fertility-clinic network (infertility solutions); also targeted at JapanUnder development. Regulatory and clinical evidence being built "step by step".
BioRobot divisionCombines cell-based diagnostics with automation for lab/test automationDivision created Feb 2026
Anti-metastasis drug developmentUses CTC isolation and omics data to find and validate anti-metastatic targetsDiscovery stage. Non-clinical completion guided at 3–4 years. Early out-licensing considered.
Precision / regenerative medicineIntegrated diagnosis-to-treatment value chainStrategic intent; details not disclosed

Financial Narrative

Basis and sources. Consolidated K-IFRS, fiscal years ending 31 December.

  • Revenue, operating income and net income FY2021–FY2025: Butler.works and ETFshopping summaries of DART.

  • FY2025 exact figures: DART preliminary results disclosure (Digital Today, 13 Feb 2026).

  • FY2024 and FY2025 balance-sheet totals: DART-based KorMedi and Digital Today reports.

  • FY2024 cash and gross profit: Craft.co.

  • FY2025 cost of sales: ValueLine (DART-sourced).

  • EPS: ETFshopping (DART).

Blank cells mean the item is not publicly disclosed in sources reviewed.

Margins (chartable)

Margins are derived from rounded figures. FY2021–FY2022 margins are distorted by negligible revenue.

Revenue CAGR FY2021–FY2025. About 205% per year (from KRW 0.3 B to KRW 26.05 B). This is mathematically correct but analytically misleading: almost all of the growth is acquired (ExperTox from 2023, Genomecare from August 2024) or comes from distribution. Organic CTC revenue growth is not separately disclosed.

Quarterly trajectory (chartable)

Notes:

  • Q3 2025: Thinkpool (DART).

  • Q1 and Q2 2026: ETFshopping and Seoul Economic Daily. Q1 2026 revenue +14.0% YoY, operating loss narrowed from KRW 2.4 B. Q2 2026 revenue +8.7% YoY.

  • Q2 2025 operating income, Q1/Q2 2025 net income and all Q4 2025 figures are back-calculated from reported YoY changes and full-year totals. They are approximate and not company-reported quarterly figures.

Trailing twelve months to Q2 2026 (derived). Revenue about KRW 27.35 B; operating loss about KRW 6.6 B; net loss about KRW 10.5 B. The net loss is consistent with Investing.com's TTM EPS of KRW −457 × 23.1 M shares ≈ KRW −10.6 B.

Balance sheet (chartable)

Notes:

  • The parent's separate total assets were KRW 54.64 B at FY2025 (JobKorea).

  • Current ratios are from THE VC's AI summary: 539.2% (2023), 1,318.8% (2024), 286.6% (most recent). The FY2024 spike likely reflects cash from the December 2023 KRW 55.5 B raise. Morningstar reports a TTM current ratio of 2.93x and a quick ratio of 2.59x (April 2026).

  • Implied equity at H1 2026 is about KRW 33 B. This is derived from Butler's P/B of 2.10x at KRW 3,025 and is not a reported figure.

  • Net debt, working capital and debt maturities are not publicly disclosed in sources reviewed. for disclosed convertible bonds.

Cash flow

Cash-flow statement line items were not accessible in sources reviewed. No cash dividends or buybacks have been paid in the company's listed history; it has used treasury shares only for employee compensation (60,000 shares disposed in Sep–Nov 2025).

Commentary: trends, inflections, drivers

Revenue inflection is acquisition-led. Revenue of KRW 0.3–1.2 B a year from 2018 to 2022 shows that the CTC franchise did not achieve commercial scale in its first eight years after listing. The step-ups in FY2023 (+318.6%) and FY2024 (+242.6%) coincide with the consolidation of ExperTox (January 2023) and Genomecare (from 21 August 2024). FY2025 (+138.8%) is the first full year of Genomecare. The company's own explanation of FY2025 growth is "expansion of new businesses and growth of consolidated subsidiary Genomecare". Q1 2026 growth (+14%) was attributed to Genomecare and new Japanese revenue that began in late 2025.

Growth is decelerating sharply now that acquisitions have annualized. YoY growth slowed from +129% in Q3 2025 to +14% in Q1 2026 and +8.7% in Q2 2026. The next inflection depends on organic drivers (Japan CTC, PRP, NIPT/PGT volume), not M&A.

Losses are narrowing but persistent.

  • Operating losses have stayed in a narrow band of KRW 10.7–12.9 B for four years, then improved to KRW 8.16 B in FY2025. H1 2026 operating loss was KRW 2.7 B versus about KRW 4.3 B in H1 2025.

  • Improvement comes mostly from Genomecare's profit contribution and SG&A cuts. Management cited "company-wide efficient SG&A reduction".

  • The parent's separate operating loss (KRW −7.77 B in FY2025) shows the CTC business is still structurally unprofitable.

Net losses exceed operating losses. Net loss exceeded operating loss by about KRW 4.2 B in FY2025 and KRW 6.4 B in FY2024. Non-operating losses therefore account for a substantial share. Plausible contributors include valuation losses on convertible instruments, impairments and financial costs. The specific breakdown is not publicly disclosed in sources reviewed.

Gross margins are low for a diagnostics company. About 21.5% in FY2025 (cost of sales KRW 20.44 B). This reflects the mix: lab-service cost structures plus pass-through distribution revenue. The cost-of-sales breakdown (ValueLine, TTM) shows raw materials of about KRW 18.8 B. That is consistent with significant merchandise and consumables content.

Balance-sheet erosion. Total equity fell from KRW 48.9 B to KRW 36.0 B in FY2025, roughly equal to the net loss. Implied equity is about KRW 33 B at H1 2026. The KRW 5.2 B 7th-series CB issued in May 2026 for operating funds signals that the company keeps returning to capital markets. Cash runway cannot be calculated precisely without the cash-flow statement, but the cadence of financing suggests a runway measured in a few years at most at current burn, absent further improvement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (As Reported, Translated) Overview

Segment (as reported, translated)Korean label (approximate)ContentsMain entities

Liquid Biopsy Application Business

Liquid Biopsy 응용사업

CTC services (pharma contract analysis, Japan CTC services), Smart Biopsy™ instruments/chips/kits, equipment contracts, medical-device distribution, health-functional food sales

Cytogen, Inc. (parent); CytoGen Japan

Genome Technology Development & Analysis Services

게놈기술개발 및 분석서비스

NIPT, PGT (Genobro™), other reproductive genomic testing

Genomecare (subsidiary until 30 Sep 2026; merged into parent on 1 Oct 2026)

Toxicology & Molecular Diagnostics

독성 및 분자진단

US CLIA/CAP toxicology testing; molecular diagnostics expansion

ExperTox Inc. (Houston, Texas)

Segment Revenue

SegmentShare of revenue, 2026 Q2 basis (%)Implied H1 2026 revenue (KRW Bn, derived)

Liquid Biopsy Application

486.3

Genome Technology & Analysis

476.2

Toxicology & Molecular Diagnostics

60.8

Total

101 (rounding at source)

13.2

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

Genome Technology & Analysis: Genomecare standalone revenue (full year)

——10.96

Parent company separate revenue (Cytogen, Inc.)

0.875.2612.49

Consolidated revenue (all segments)

3.210.926.1

Segment Metric Details

Segment metric (KRW Bn)FY2025

Genomecare standalone operating income

2.95

Genomecare standalone net income

2.69

Genomecare standalone operating margin (%)

26.9

Parent separate operating income

-7.77

Consolidated operating income

-8.16

Group Entities

EntityCountryOwnershipStatus / function

Cytogen, Inc.

Korea

Listed parent

CTC platform, R&D, distribution; since 1 Oct 2026 also runs NIPT/PGT (former Genomecare)

ExperTox Inc.

USA (Houston, TX)

100% (acquired Jan 2023)

CLIA/CAP toxicology lab; US base for CTC services

CytoGen Japan

Japan (Tokyo)

100% (119,999 shares; book value KRW 1.093 B per Q1 2026 report)

CTC analysis services, Japanese market development

CytoGen Health Inc.

USA

—

US subsidiary established 2022

Genomecare Co., Ltd.

Korea

Was 99.89%, later 100%; dissolved by absorption merger on 1 Oct 2026

Merged into parent

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

0.30.83.210.9126.05

Revenue growth YoY (%)

-15.9118.7318.6242.6138.8

Gross profit (KRW Bn)

———1.75.6

Operating income (KRW Bn)

-12.9-11.5-11.8-10.7-8.16

Net income (KRW Bn)

-10.9-18.8-15.8-17.1-12.33

EPS basic (KRW)

-642-1,063-862-758-535

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

———15.621.5

Operating margin (%)

-4,300-1,438-369-98.1-31.3

Net margin (%)

-3,633-2,350-494-156.9-47.3

Income Statement

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

5.66.37.636.56.46.8

Operating income (KRW Bn)

-2.4-1.9-1.31-2.6-1.5-1.2

Net income (KRW Bn)

-2.5-2.8-1.62-5.4-1.3-2.2

Balance Sheet and Financial Ratios (x)

MetricFY2023FY2024FY2025

Total assets (KRW Bn)

—72.562.2

Cash and equivalents (KRW Bn)

—31.2—

Total liabilities (KRW Bn)

—23.526.2

Total equity (KRW Bn)

—48.936.0

Current ratio (x)

5.3913.192.87

Financial Analysis

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Dividends paid

00000

Share buybacks

00000

Instrument by Date

DateInstrumentAmount (KRW Bn)CounterpartyTerms

Nov 2018

IPO

15.6–20.4 (band)

Public

Band KRW 13,000–17,000

Sep 2020

3rd CB

10.0

Jeil Bio Fund (7.0), T&C Asset Mgmt (3.0)

0% coupon; conversion price KRW 20,200; maturity 25 Sep 2025

28 Dec 2023

Third-party rights issue

40.0

CanDx Holdings

3,125,000 shares (KRW 12,800/share implied)

28 Dec 2023

CB

15.5

CanDx Holdings

Originally KRW 30 B, cut to KRW 15.5 B and payment brought forward.

Aug 2024

Third-party rights issue

6.5

Theragen Etex

706,445 shares (3.05%)

May 2026

7th CB (private, bearer, unsecured)

5.2—

0% coupon; conversion price KRW 5,445; conversion from 26 May 2027

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025 valueBasis

ROE (%)

-29.0

Net income / average equity ((48.9 + 36.0)/2)

ROE (%), vendor

-19.96 (normalized, Morningstar); -33.22 (ValueLine)

Vendor methodologies differ

ROA (%)

-18.3

Net income / average assets ((72.5 + 62.2)/2)

ROA (%), vendor

-10.52 (normalized, Morningstar)

—

ROIC (%), vendor

-10.03 (normalized, Morningstar)

—

Current ratio (x)

2.87–2.93

THE VC; Morningstar

Total liabilities / equity (x)

0.73

26.2 / 36.0

Equity ratio (%)

57.9

36.0 / 62.2

Net debt / EBITDA

Not meaningful (negative EBITDA; net debt not disclosed)

—

Interest coverage (x)

-4.96

Morningstar, TTM April 2026

Asset turnover (x)

0.39

26.05 / average assets 67.35

Region revenue (KRW Bn)

Region revenue (KRW Bn)FY2023FY2024FY2025

Domestic (Korea)

——23.38

Export / overseas

——2.66

Total

3.210.9126.05

TTM revenue split (KRW Bn)

TTM revenue split (KRW Bn)TTM Mar 2025TTM Jun 2025TTM Sep 2025TTM Dec 2025

Domestic

11.5718.5923.0723.38

Export

4.132.212.022.66

Segment Overview

SegmentPrimary geography

Genome Technology & Analysis (Genomecare)

Korea, about 100%

Toxicology & Molecular Diagnostics (ExperTox)

United States, about 100%

Liquid Biopsy Application

Korea (CTC services, distribution, equipment) plus Japan (CytoGen Japan services from late 2025)

Share Price History

DatePrice (KRW)ContextSource

Nov 2018

13,000–17,000 (IPO band)

KOSDAQ listing

Medical Times

16 Dec 2019

11,900

Market cap KRW 67 B; 5.634 M shares

Kiwoom Securities

27 Oct 2021

66,100

Pre-dates an apparent roughly 3x increase in share count by 2023; not comparable without adjustment

Asia Economy

Early Jan 2024

16,200

Start of 2024

Pharm Edaily

27 Nov 2024

4,850

During management dispute

Pharm Edaily

5 Nov 2025

2,975—

Digital Today

19 Dec 2025

6,250 (intraday limit-up 6,700)

Theme rally

JoongAng Economy News

22 Dec 2025

8,120 (limit-up)

Animal-alternative testing bill

Seoul Economic Daily

30 Dec 2025

8,990

Market cap about KRW 207.9 B

BioTimes

Dec 2025 / Jan 2026

11,200—

TipRanks, Investing.com

24 Feb 2026

4,930

After CEO change

Money Today

13 Apr 2026

3,955

Market cap KRW 91.7 B

Morningstar

29 Jul 2026

2,830

Merger announcement day (−6.45%)

KorMedi

10 Aug 2026

3,670

EGM day (+7%)

KorMedi

1 Oct 2026

3,225

Merger completion (+6.09%)

Money Today

12 Oct 2026

2,770

Market cap KRW 64.06 B

Investing.com

14 Oct 2026

2,865

Market cap about KRW 66.5 B

StockHub

Approximate Change by Period

PeriodApproximate changeBasis

1-year

About −4%

KRW 2,975 (5 Nov 2025) to KRW 2,865 (14 Oct 2026); window not exactly 12 months

Since 2024 start

About −82%

KRW 16,200 to KRW 2,865

From December 2025 peak

About −74%

KRW 11,200 to KRW 2,865

3-year

Strongly negative

Judal.co.kr's April 2026 "3-year price index 26.59%" metric is not interpretable without methodology

5-year

Not computed

—

Valuation Multiples

MultipleCytogenBasis

P/E

Not meaningful (loss-making)

TTM EPS KRW −457 (Investing.com)

P/B (x)

About 1.8–2.1

KRW 66.3 B market cap / FY2025 equity KRW 36.0 B = 1.84x; Butler shows 2.10x at KRW 3,025

P/S, TTM (x)

About 2.4

KRW 66.3 B / TTM revenue about KRW 27.35 B (derived)

EV/Sales; EV/EBITDA

Not computed

TipRanks EV field appears corrupted ("₩65.07K").

Peer comparison

Not compiled

—

Capital Instruments

InstrumentIssue datePrincipal (KRW Bn)Coupon / YTM (%)Conversion price (KRW)MaturityStatus

3rd CB

Sep 2020

10.0

0 / 0

20,200

25 Sep 2025

—

CB to CanDx

28 Dec 2023

15.5————

7th CB (private)

May 2026

5.2

0 / 0

5,445—

Outstanding; conversion from 26 May 2027

Analyst Conclusions

Management guidance

No formal quantitative guidance is published. Qualitatively, management signals:

  • a "turnaround" foundation from M&A synergies and visible overseas revenue (Q1 2026 release)

  • cost synergies and simpler decision-making from the Genomecare merger

  • Japan expansion across three product lines

  • a 3–4 year horizon to complete non-clinical work on anti-metastasis candidates

Consensus expectations

None (no sell-side coverage).

Bull case

  1. Hidden profitable core. Genomecare earned KRW 2.95 B of operating profit in FY2025 at about a 27% margin. If CTC losses are cut through merger synergies and SG&A discipline, consolidated breakeven is within reach. TTM operating loss has already narrowed to about KRW 6.6 B, against KRW 10.7 B in FY2024.

  2. Asset value versus market cap. At about KRW 66 B market cap (about 1.8–2.1x book), investors pay roughly the price of a profitable domestic NIPT/PGT lab plus the US lab and Japan subsidiary. That leaves the CTC platform (52 patents, NIH/NCCH validation) and the anti-metastasis option close to free.

  3. Japan as a real growth vector. Revenue began in late 2025. A premium out-of-pocket market with higher CTC awareness, NCCH collaboration and CMIC channel access could make Japan the first market where CTC testing scales commercially for Cytogen.

Bear case

  1. Growth has stalled after the acquisitions annualized. Revenue growth decelerated to +8.7% YoY in Q2 2026. The underlying CTC business generated minimal revenue for a decade. Low gross margins (about 21.5%) and distribution revenue cap profit potential.

  2. Governance and overhang. The founder was removed as CEO by dismissal, the controlling PE-backed vehicle is selling shares (−758,794 shares, Sep 2026), and the board is controller-dominated. Further contests or a disorderly exit by CanDx are plausible.

  3. Funding and dilution treadmill. Equity fell 26% in FY2025 and the company issued another CB in May 2026. With 1.02 M options outstanding and an expanding R&D agenda (drug discovery, bio-robotics, PRP), further dilutive raises are likely before sustainable profitability.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
About 12 Nov 2026Q3 2026 results: first post-merger quarter commentary; YoY growth rate; operating loss trend
Nov 2026Delivery and acceptance of the KRW 1.05 B Gangwon automation system (contract end 5 Nov 2026)
Q4 2026 – Q1 2027Segment-reporting presentation after the merger; FY2026 results (around Feb–Mar 2027)
OngoingCanDx Holdings large-holding reports (further stake reductions or a block sale)
OngoingBoard dynamics with founder Jeon; any renewed shareholder activism
2026–2027Japanese revenue disclosure; PRP system regulatory progress; cell-based NIPT development
Feb 2027CEO Ahn's director term expiry (20 Feb 2027); re-appointment at the March 2027 AGM
From 26 May 20277th CB conversion window opens (KRW 5,445 conversion price, well above current price)
OngoingNational R&D project milestones; anti-metastasis target nominations
OngoingKorean animal-alternative testing legislation (theme catalyst)

Analyst verdict

Cytogen today is two businesses tied together by a controlling shareholder's diversification strategy.

The first is a credible, profitable Korean reproductive-genomics laboratory. Genomecare, now merged into the parent, produced KRW 10.96 B of revenue and a 27% operating margin in FY2025. It is the reason consolidated revenue grew roughly 87-fold between FY2021 and FY2025 and the reason losses are narrowing.

The second is the original CTC liquid biopsy franchise. It is scientifically differentiated by live, label-free cell capture and validated through collaborations with NIH, Japan's NCCH and leading Korean hospitals. Commercially, however, it remains marginal more than seven years after its 2018 IPO, and it now carries a broadening, capital-hungry agenda: Japanese services, PRP automation, bio-robotics and anti-metastasis drug discovery.

The market has priced this tension harshly. The shares trade near KRW 2,800, about 74% below the speculative December 2025 peak. That implies a market capitalization of about KRW 66 B, or roughly 2x book and 2.4x trailing sales. On a sum-of-the-parts view this valuation is undemanding if Genomecare's earnings are durable and CTC cash burn is contained.

However, three factors justify a significant discount and argue against treating Cytogen as a conventional diagnostics value play:

Governance: a controller-dominated board, the founder's dismissal and the controller's stake sales.

Funding: recurring convertible-bond issuance and 26% equity erosion in FY2025.

Growth: decelerating top-line growth now that acquisitions have annualized.

The investment case rests on evidence that has not yet appeared:

  • consolidated operating breakeven after the merger

  • disclosed and growing Japanese CTC revenue

  • no further dilutive financing

  • an orderly resolution of CanDx's ownership intentions

Until then, Cytogen is best characterized as a high-risk, event-driven small cap whose fundamental floor is set by its NIPT/PGT franchise. Upside optionality lies in Japan and CTC-derived therapeutics, and the principal risks are governance and dilution.


APPENDIX A: DATA GAPS AND DISCREPANCIES

ItemIssue
Founding yearDART-based sources: 18 Mar 2010. Some aggregators: 2013 (likely error). Job portal: 16 Mar 2010.
Head officeRegistry shows Gwacheon (since Mar 2026); some data vendors still list Seoul (Songpa)
Employees39 (annual report, domestic parent) vs 43–47 (pension data) vs 50–56 (vendors)
EPSFY2025 EPS KRW −535 (DART via ETFshopping) vs KRW −236.49 (Investing.com "earnings release" row; basis unclear)
Genomecare acquisition priceKRW 13.18 B (Cytogen filing, 99.88%) vs KRW 6.8 B (third-party database, Theragen's portion)
CanDx current stake31.96% (FY2025 report) vs about 28.7% implied after the Sep 2026 reduction vs 30.79% shown by an aggregator against a Sep 2026 date (possibly stale)
CTC market sizeUS$5.5 B to US$14 B (2024–2025) depending on research house
Q2 2025 and Q4 2025 quarterly figuresBack-calculated, not directly reported in sources reviewed
R&D expense, cash flow, debt detail, auditor, ISINNot accessible in sources reviewed; available in Korean DART filings

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior rolesEducationAge / birthCompensation

Ahn Ji-hoon (안지훈)

CEO (sole Representative Director); inside director

Joined 1 Feb 2024 (strategy, new business, M&A); co-CEO 2 Jan 2025; sole CEO 20 Feb 2026; director term to 20 Feb 2027

Strategic Planning Head, Samkwang Medical Foundation; CEO, Samkwang LabTree (Mar 2019–Jan 2021); CEO, SML Genetree (Mar 2016–Feb 2023)

PhD coursework (ABD), Science & Technology Management, Korea University

Born Oct 1981 (44)

Not disclosed (below the KRW 500 M individual disclosure threshold or not reported); granted 80,000 stock options at KRW 3,280 (Aug 2026)

Jeon Byung-hee (전병희)

Founder; inside director (non-executive role since Feb 2026)

CEO from founding until July 2024; co-CEO Jan 2025–Feb 2026 (removed by board)

Founder

—

Born 1959 (Yahoo Finance)

—

Son Young-woong (손영웅)

Executive Director (전무); inside director

————

80,000 stock options (Aug 2026); holds 0.14%

Jung Yun-young (정윤영)

Executive Director (전무)

————

80,000 stock options (Aug 2026)

Lee Jong-gil (이종길)

Senior Managing Director

————

Holds 2.03% (FY2025)

Jang Kang-won (장강원)

Director (이사, officer)

————

20,000 stock options

Park Se-hyung (박세형)

Principal Researcher, Diagnostics Division

—————

“—” = not publicly disclosed.

Board of Directors — Ahn Ji-hoon

NameCategoryAppointedBackgroundAffiliation

Ahn Ji-hoon

Inside director, CEO

2024

See above

CanDx-aligned (per thebell)

Jeon Byung-hee

Inside director

Founder

Founder

Founder

Son Young-woong

Inside director, Executive Director

——

Founder-aligned (per thebell)

Min Seung-ki (민승기)

Non-executive director

Re-elected 10 Aug 2026 (3-year term)

CEO, Excelsior Capital Korea; formerly VP Keystone PE, VP HTC Financials, EVP Hyundai Securities, EVP Heungkuk Asset Management, EVP Heungkuk Life; born Sep 1962

CanDx / Excelsior

Seo Seok-chan (서석찬)

Non-executive director

Elected 10 Aug 2026 (3-year term)

CEO, Wells Bio; formerly strategy director, B-Light Investment (an Access Bio subsidiary and CanDx co-investor); VP AI business, MHN City; branch manager, OSTEM USA San Francisco; born Aug 1975

CanDx-aligned (inferred via B-Light)

Noh Kyung-hwa (노경화)

Non-executive director

Mar 2025

—

CanDx-aligned (per thebell count; not individually confirmed)

Chae Gwang-seok (채광석)

Outside director

Oct 2023 EGM

Former CEO, DS Asset Management; Songhyun Investment; Hanwha Asset Management

Not specified

Bang Nam-ho (방남호)

Outside director

Sep 2024

—

Not specified

Jang In-geun (장인근)

Outside director

12 Mar 2025 EGM (company nominee)

—

Not specified

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

28 Feb 2024

Sa Cheol-gi appointed co-CEO alongside founder Jeon

Post-CanDx change of control

5 Jul 2024

Jeon resigns as co-CEO; Sa becomes sole CEO

Followed board votes in which founder-aligned directors (Jeon, Kim Jung-won, Nam Kwang-min) were outvoted on reorganization and M&A items

2 Jan 2025

Sa resigns; Jeon and Ahn appointed co-CEOs

Settlement of the 2024 management dispute. Jeon took responsibility for the CTC business; Ahn for new businesses.

20 Feb 2026

Jeon removed as co-CEO by board resolution; Ahn sole CEO

Thebell flagged that dismissal rather than resignation leaves "embers of conflict". The company said Jeon agreed and the aim was management efficiency.

Major Shareholders

RankHolderCategoryStake (%)
1

CanDx Holdings LLC

Investment vehicle (Excelsior Capital Korea-led)

31.96
2

Jeon Byung-hee

Inside director, founder

8.84
3

Kiwoom High-Growth Gazelle Fund

SME/venture investment fund

4.49
4

Kim Jin-wook

Major individual shareholder

3.62
5

Lee Jong-gil

Senior Managing Director

2.03
6

T&C Asset Management

Private fund manager

1.73
7

Son Young-woong

Executive

0.14
—

Minority shareholders (19,612 holders)

Retail

40.72
—

National Pension Service

Listed as a holder (THE VC, updated Jul 2026)

Stake not disclosed

—

Foreign investors

—

About 2% (Dec 2025)

Competitive Landscape

Competitors by Segment

SegmentCompetitorHQPositioning vs Cytogen

CTC platforms

Menarini Silicon Biosystems (CellSearch®; DEPArray™)

Italy / US

CellSearch is the first FDA-cleared CTC system (prognosis in metastatic breast, prostate and colorectal cancer); dominant installed base; EpCAM-based. Far larger, with regulatory moat.

CTC platforms

ANGLE plc (Parsortix®)

UK

Size-based, label-free CTC capture (closest technological analogue); FDA-cleared for metastatic breast cancer (2022)

CTC / single-cell liquid biopsy

Epic Sciences

US

CTC-based diagnostic tests; pharma services

CTC / microfluidics

Fluxion Biosciences; Cynvenio Biosystems

US

Microfluidic CTC isolation for research

CTC (Japan)

Sysmex Corporation

Japan

Developed a microfluidic CTC capture device (2023); strong Japanese IVD incumbent in Cytogen's target market

ctDNA liquid biopsy (substitute)

Guardant Health; GRAIL; Natera

US

ctDNA tests dominate clinical liquid biopsy (CGP, MCED, MRD). Cytogen positions CTC as complementary rather than competing.

Korean liquid biopsy / genomics

Macrogen; Labgenomics; EDGC

Korea

Labgenomics and EDGC also pursue US liquid biopsy expansion; Macrogen is both partner and competitor

NIPT / PGT (Korea)

GC Genome; Theragen Bio / Theragen Etex group; Labgenomics; EDGC

Korea

Domestic NIPT/PGT competitors. Theragen Etex was the former owner of Genomecare.

US toxicology labs

Large reference labs (Quest Diagnostics, Labcorp) and regional toxicology labs

US

ExperTox is a small regional player

CTC/organoid theme peers (Korean market)

Other KOSDAQ organoid / animal-alternative testing companies

Korea

Compete for the same investor theme

Peer Comparison FY2025

MetricCytogen (FY2025)Menarini Silicon Biosystems

Revenue

KRW 26.05 B (about US$19 M at about 1,400 KRW/US$; indicative)

Not separately disclosed (private division of Menarini Group)

Revenue growth (%)

138.8—

Operating margin (%)

-31.3—

FDA-cleared CTC product

No

Yes (CellSearch)

“—” = not publicly disclosed.

Company Snapshot

$18.3M

Revenue

43

Employees

2010

Founded

Gwacheon, South Korea

Headquarters

SWOT Analysis

Strengths

  • Profitable core cash generator: Genomecare FY2025 revenue KRW 10.96 B, operating income KRW 2.95 B (26.9% margin), net income KRW 2.69 B (merger filing, Jul 2026)
  • Rapid consolidated scale-up: Revenue rose from KRW 0.3 B (FY2021) to KRW 26.05 B (FY2025); +138.8% in FY2025 (DART)
  • Narrowing losses: Operating loss improved from KRW 10.7 B (FY2024) to KRW 8.16 B (FY2025); Q1 2026 operating loss KRW 1.5 B vs KRW 2.4 B YoY
  • Differentiated CTC technology: Size-based, label-free live-CTC capture; 79–82% recovery; analysis time cut from 3 h to 30 min (company data; Biospectator; Dealsite)
  • Multinational lab footprint: US CLIA/CAP lab (ExperTox, US$7.3 M acquisition, 2023); CytoGen Japan (2024); GCLP lab in Korea
  • Institutional credibility and non-dilutive funding: NIH platform supply (2022); NCCH Japan collaboration (2023); 11 national R&D projects; 52 patents

Weaknesses

  • Chronic losses: Net losses every year: KRW −10.9 B, −18.8 B, −15.8 B, −17.1 B, −12.3 B (FY2021–FY2025)
  • Low gross margin: About 21.5% in FY2025 (cost of sales KRW 20.4 B on KRW 26.05 B revenue; ValueLine/DART); 15.6% in FY2024 (Craft)
  • Organic CTC revenue never scaled: Revenue below KRW 1.2 B every year 2017–2022 before acquisitions (ETFshopping/DART)
  • Eroding equity: Equity fell from KRW 48.9 B (FY2024) to KRW 36.0 B (FY2025); implied about KRW 33 B at H1 2026
  • Decelerating growth: YoY revenue growth: +129% (Q3 2025), +14% (Q1 2026), +8.7% (Q2 2026)
  • Revenue quality: Part of the "Liquid Biopsy application" segment is low-margin distribution (medical gloves: KRW 1.5 B in Q3 2024; thebell)

Opportunities

  • Japanese premium testing market: Japanese revenue from late 2025; three-pillar Japan plan (CTC, PRP, prenatal); BioJapan 2026; company cites about ¥230 B Japanese liquid biopsy market
  • Reproductive-medicine adjacencies: Cell-based NIPT, embryo-biopsy QC and PRP automation planned to leverage Genomecare's clinic network (Jul 2026 merger disclosure)
  • Policy tailwind for fertility: Infertility-treatment births rose from 7% to 11% of births (2020–2023, MoHW)
  • Animal-alternative testing / organoids: Proposed Korean law drove limit-up trading in Dec 2025; CTC organoid drug-sensitivity capability
  • Anti-metastasis out-licensing: Programme launched Jul 2026; management targets early-stage licence-out after efficacy and safety validation
  • Cost synergies from merger: Management cites duplicate-function integration and simplified decision-making after the 1 Oct 2026 merger

Threats

  • Governance conflict recurrence: 2024 Hyulim Networks EGM litigation and CB injunction; founder removed (not resigned) as CEO in Feb 2026; thebell flagged lingering conflict
  • Controlling-shareholder overhang: CanDx reported a 758,794-share decrease (2 Sep 2026); PE-style holder may exit
  • Dilution: 7th CB (KRW 5.2 B, conversion price KRW 5,445); 1,016,791 options outstanding
  • Technology substitution: ctDNA leaders (Guardant, GRAIL, Natera) dominate clinical liquid biopsy
  • Incumbent regulatory moats: CellSearch and Parsortix hold FDA clearances; Cytogen has none disclosed
  • Share-price volatility / theme risk: Shares rose from KRW 4,000 to over KRW 8,990 in December 2025 on a legislative theme, then fell to about KRW 2,800 by October 2026

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
21 May 2025Media attention on Genomecare as a beneficiary of presidential candidates' fertility and pregnancy support pledgesPolicy tailwind for NIPT/PGT
Aug 2025H1 2025 report filed (13 Aug 2025)Routine
11 Sep 2025Decision to dispose of 60,000 treasury shares (KRW 160.2 M) for employee compensationMinor; staff retention
5 Nov 2025KRW 1.05 B digital lab-on-chip automation system contract with Gangwon Regional Public Procurement ServiceFirst sizeable government equipment order (9.62% of FY2024 revenue)
5–11 Nov 2025Officers receive treasury-share bonuses (e.g. Executive Director Jung Yun-young, 2,016 shares at KRW 2,975)Insider alignment
Nov 2025Large-holding report: founder-led reporting group 49.84% → 49.12%Confirms concert-party structure
13 Nov 2025Q3 2025 results: revenue KRW 7.63 B (+129% YoY), operating loss KRW 1.31 B, net loss KRW 1.62 BBest quarter of operating performance in 2025
15–19 Dec 2025Shares rise from about KRW 4,000 to KRW 6,250; intraday limit-up (KRW 6,700) on 19 DecSpeculative momentum
22 Dec 2025Second consecutive limit-up (KRW 8,120), attributed to a proposed animal-alternative testing bill (organoid theme)Theme-driven re-rating; no company disclosure
30 Dec 2025Shares close at KRW 8,990; market cap about KRW 207.9 B; 9M 2025 revenue about KRW 19.5 B (+266%)Peak valuation zone (52-week high KRW 11,200)
13 Feb 2026FY2025 preliminary results: revenue KRW 26.05 B (+138.8%), operating loss KRW 8.16 B, net loss KRW 12.33 BRecord revenue; losses narrowed
20 Feb 2026Founder Jeon removed as co-CEO; Ahn Ji-hoon sole CEOConsolidates CanDx control; governance risk flagged by thebell
24 Feb 2026BioRobot division created; strategy expands to precision/regenerative medicine and infertility solutionsScope expansion
20 Mar 2026FY2025 annual report filedRoutine
Mar 2026Head office relocated to GwacheonOperational
Apr 2026Shares trade around KRW 3,955–3,975 (Morningstar, 13–14 Apr)De-rating of more than 60% from peak
14–15 May 2026Q1 2026 results: revenue KRW 6.4 B (+14%), operating loss KRW 1.5 B (vs KRW 2.4 B), net loss KRW 1.3 B (40%+ improvement); Japan revenue citedTurnaround narrative
18 May 20267th CB, KRW 5.2 B (conversion price KRW 5,445; conversion from 26 May 2027) for operating fundsOngoing funding need; potential dilution
6–7 Jul 2026Anti-metastasis drug development programme announcedNew R&D vector; long-dated
29 Jul 2026Board resolves to absorb Genomecare (1:0, no new shares)Structural simplification; shares fell 6.45% that day
10 Aug 2026EGM: Min Seung-ki re-elected, Seo Seok-chan elected (non-executive); 400,000 stock options approved; shares +7%Board reinforcement for controlling shareholder
13 Aug 2026H1 2026 results: Q2 revenue KRW 6.8 B (+8.7%), operating loss KRW 1.2 B, net loss KRW 2.2 BGrowth slowing
31 Aug 2026Board approves merger in lieu of shareholders' meeting (dissent below 20%)Merger cleared
2 Sep 2026CanDx large-holding report: −758,794 sharesControlling shareholder trimming stake; overhang
Sep 2026Two national R&D projects selectedNon-dilutive funding
1 Oct 2026Merger completed; "Genomecare by CytoGen" brand launched; shares +6.09% to KRW 3,225Integration milestone
8 Oct 2026BioJapan 2026: Japanese strategy across CTC, PRP and prenatal testing; targets the premium non-reimbursed segmentJapan commercialization
12–14 Oct 2026Shares at KRW 2,770–2,865; market cap about KRW 64–66 B; near 52-week lowValuation reset
15 Oct 2026Scheduled merger registration dateAdministrative

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Genome Technology & Analysis: Genomecare standalone revenue (full year) was KRW 10,960 Mn in FY2025.
Cytogen, Inc. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Genome Technology & Analysis: Genomecare standalone revenue (full year)——10,960
Parent company separate revenue (Cytogen, Inc.)8705,26012,490
Consolidated revenue (all segments)3,20010,90026,100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DART preliminary FY2025 results disclosure, via Digital Today (13 Feb 2026) (digitaltoday.co.kr)
  2. KIND Q1 2026 quarterly report (extracts) (kind.krx.co.kr)
  3. Genomecare merger decision, via KorMedi (29 Jul 2026) (kormedi.com)
  4. Merger decision, via Chickstock (29 Jul 2026) (chickstockfi.com)
  5. Merger completion, Money Today (1 Oct 2026) (mt.co.kr)
  6. Merger rationale, Seoul Economic Daily (29 Jul 2026) (sedaily.com)
  7. Merger approval, Yakup (m.yakup.com)
  8. EGM results Aug 2026, KorMedi (kormedi.com)
  9. Stock options Aug 2026, KorMedi (kormedi.com)
  10. CEO change Feb 2026, Nate/Digital Today (m.news.nate.com)
  11. CEO change analysis, thebell (Feb 2026) (m.thebell.co.kr)
  12. Sole-CEO strategy, Money Today (24 Feb 2026) (mt.co.kr)
  13. Co-CEO appointment Jan 2025, Edaily (edaily.co.kr)
  14. Q1 2026 results, Seoul Economic Daily (sedaily.com)
  15. Quarterly results table, ETFshopping (etfshopping.com)
  16. Multi-year financials and EPS, ETFshopping (etfshopping.com)
  17. Shareholders/employees, ETFshopping (etfshopping.com)
  18. Butler.works company summary (segments, 5-year P&L) (butler.works)
  19. Goinsider.kr major shareholders (goinsider.kr)
  20. ValueLine income statement (domestic/export, cost of sales) (valueline.co.kr)
  21. ValueLine company summary (valueline.co.kr)
  22. JobKorea company financials (separate) (jobkorea.co.kr)
  23. Saramin corporate history (saramin.co.kr)
  24. THE VC company profile (thevc.kr)
  25. THE VC financials (thevc.kr)
  26. THE VC Excelsior Capital Korea (thevc.kr)
  27. CanDx acquisition, Biospectator (biospectator.com)
  28. CanDx financing, Medigate News (medigatenews.com)
  29. Genomecare acquisition, HIT News (Aug 2024) (hitnews.co.kr)
  30. Theragen Etex side, Dealsite (dealsite.co.kr)
  31. Management dispute, Pharm Edaily (pharm.edaily.co.kr)
  32. Hyulim EGM petition, The Big Data (thebigdata.co.kr)
  33. EGM Mar 2025, Bloter (bloter.net)
  34. Dispute resolution and 2025 plans, thebell (Mar 2025) (m.thebell.co.kr)
  35. Korean Wikipedia, 싸이토젠 (ko.wikipedia.org)
  36. ExperTox acquisition, Biospectator (biospectator.com)
  37. US expansion interview, Hankyung/Daum (Feb 2023) (v.daum.net)
  38. NCCH collaboration, KED Global (kedglobal.com)
  39. Japan entry, eToday (etoday.co.kr)
  40. BioJapan 2026, Financial News (fnnews.com)
  41. CMIC agreement, Biospectator (biospectator.com)
  42. Macrogen MOU, Biospectator (biospectator.com)
  43. Pancreatic cancer national project, Medigate (medigatenews.com)
  44. Gangnam Severance contract, Medigate (medigatenews.com)
  45. Technology description, Dealsite (Jul 2023) (dealsite.co.kr)
  46. CTC recovery rate, Biospectator (biospectator.com)
  47. KoreaRatings technology report (Aug 2024) (stock.pstatic.net)
  48. Company IR deck (Jul 2023) (file.alphasquare.co.kr)
  49. Kiwoom report (Dec 2019) (file.alphasquare.co.kr)
  50. IPO filing, Medical Times (medicaltimes.com)
  51. 3rd CB and conversions, Asia Economy (core.asiae.co.kr)
  52. Ascent Bio Fund contest, Asia Economy (core.asiae.co.kr)
  53. Gangwon procurement contract, Digital Today (digitaltoday.co.kr)
  54. Q3 2025 results, Thinkpool (m.thinkpool.com)
  55. 7th CB, Bullstory (bullstory.io)
  56. Anti-metastasis programme, Money Today (mt.co.kr)
  57. Genomecare/fertility policy, Money Today (May 2025) (mt.co.kr)
  58. Limit-up Dec 2025, Seoul Economic Daily (sedaily.com)
  59. Theme driver, Geumgang Ilbo (ggilbo.com)
  60. Year-end 2025 price, BioTimes (biotimes.co.kr)
  61. Price history, Investing.com (investing.com)
  62. Quote and market cap, Investing.com (investing.com)
  63. TipRanks quote (tipranks.com)
  64. Morningstar quote and ratios (morningstar.com)
  65. StockHub quote (stockhub.kr)
  66. Hankyung consensus (markets.hankyung.com)
  67. Craft.co financial summary (craft.co)
  68. Simply Wall St profile (simplywall.st)
  69. Yahoo Finance profile (nz.finance.yahoo.com)
  70. CTC market, Market Research Future (marketresearchfuture.com)
  71. CTC market, IMARC (imarcgroup.com)
  72. CTC market, SNS Insider via GlobeNewswire (globenewswire.com)
  73. CTC market, TechSci (GII Korea) (giikorea.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.